Literature DB >> 17153708

Modified endocystectomy versus pericystectomy in echinococcus granulosus liver cysts: a randomized controlled study, and the role of specific anti-hydatid IgG4 in detection of early recurrence.

Sameh B Elsebaie1, Magdy M A El-Sebae, M Emad Esmat, Majid M Nasr, Manal M Kamel.   

Abstract

The evidence based data of hydatid liver disease indicate that the level of evidence was too low to help decide between radical or conservative surgeries (level IV evidence, grade C recommendation). So, there is a need for accurately designed randomized trials with precise goals to compare pericystectomy versus a specific modified endocystectomy technique for the treatment of hepatic hydatid cysts 8 cm or less in diameter in Egyptian patients, regarding the operative time, intra-operative blood loss, complications and long-term recurrence and to test the role of anti-hydatid IgG4 in diagnosis and detection of early recurrence. 60 patients with 131 liver cysts of E. granulosus fulfilling the study criteria were randomly divided to two groups. GI: 32 patients with 69 cysts treated by modified endocystectomy and GII: 28 patients with 62 cysts treated by closed total pericystectomy. GIa included 40 cysts >5 cm in diameter (mean 6.86, SD+/-0.809) &amp; GIb 29 cysts < or = 5 cm in diameter (mean 4.17 SD+/-0.83). GIIa included 37 cysts >5 cm in diameter (mean 7.01 SD+/+0.79) &amp; GIIb 25 cysts < or = 5 cm in diameter (mean 4.04 SD+/-0.93). Preoperative evaluation included history taking, clinical examination, blood tests, specific anti-hydatid IgG4, abdominal sonography and CT scan. The operative time for dealing with each cyst was in minutes. Operative blood loss and need for blood transfusion were estimated for each patient. Specific anti-hydatid IgG4 by ELISA was used to diagnose and to detect early recurrence. Patients were followed up clinically and by ultrasonography every 3 months and for anti-hydatid IgG4 every 6 months for 24-90 months. The mean maximum operative time was in GIIa followed by GIa, GIb, then GIIb. The operative time was significantly lower in GIIb than Ib and in GIa than IIa. Seven patients (GII) had blood transfusion. The intraoperative bleeding in GI was <500 ml/ patient, and 18 patients (GII) each bled >500 ml. No intraperitoneal seedling during the follow up. 5 of 55 patients (9%) were serologically suspected of relapse or incomplete cure. One (GII) showed early recurrence at 3 months. High IgG4 antibodies were detected in patients which decreased gradually after surgery and normal after 18 months post-operation.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17153708

Source DB:  PubMed          Journal:  J Egypt Soc Parasitol        ISSN: 1110-0583


  5 in total

1.  Endocystectomy as a conservative surgical treatment for hepatic cystic echinococcosis: A systematic review with single-arm meta-analysis.

Authors:  Mohammad Al-Saeedi; Ali Ramouz; Elias Khajeh; Ahmad El Rafidi; Omid Ghamarnejad; Saeed Shafiei; Sadeq Ali-Hasan-Al-Saegh; Pascal Probst; Marija Stojkovic; Tim Frederik Weber; Katrin Hoffmann; Arianeb Mehrabi
Journal:  PLoS Negl Trop Dis       Date:  2021-05-12

Review 2.  Cystic echinococcosis in humans and animals in Egypt: An epidemiological overview.

Authors:  Abdelbaset Eweda Abdelbaset; Kinpei Yagi; Nariaki Nonaka; Ryo Nakao
Journal:  Curr Res Parasitol Vector Borne Dis       Date:  2021-11-17

3.  Hydatid cyst of spleen: a diagnostic challenge.

Authors:  Khalid Rasheed; Showkat Ali Zargar; Ajaz Ahmed Telwani
Journal:  N Am J Med Sci       Date:  2013-01

4.  Analysis of the clinical value of 18F-FDG PET/CT in hepatic alveolar echinococcosis before and after autologous liver transplantation.

Authors:  Yongde Qin; Xiaohong Li; Qizhou Zhang; Bin Xie; Xuewen Ji; Yubin Li; Amina Yiblayan; Hao Wen
Journal:  Exp Ther Med       Date:  2015-11-12       Impact factor: 2.447

5.  Biological characteristics of 18F-FDG PET/CT imaging of cerebral alveolar echinococcosis.

Authors:  Amina Yibulayin; Xiao-Hong Li; Yong-De Qin; Xiao-Yan Jia; Qi-Zhou Zhang; Yu-Bin Li
Journal:  Medicine (Baltimore)       Date:  2018-09       Impact factor: 1.889

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.